News

"As-Needed" Injections Are an Option for Wet AMD

Two-year results from the recently-completed HARBOR trial showed that some patients with wet AMD fare as well from Lucentis (ranibizumab) injections on an as-needed basis compared to a monthly basis. The original Lucentis trial recommended monthly dosing until the eye stabilized. The follow-up study, however, found that 93% of patients responded well with an average [Read More]

Lampalizumab Effective in Slowing Progression of Dry AMD

Roche Pharmaceutical has announced positive phase II results from their MAHALO phase II study of lampalizumab (aka anti-factor D). The study showed a 20.4 percent reduction in progression of advanced dry macular degeneration (geographic atrophy) at 18 months. Lampalizumab is designed to inhibit Complement Factor D, a protein that is part of the alternative complement [Read More]

Support Groups Can Improve Quality of Life

by Dan Roberts Researchers have found that facilitated patient support groups can significantly improve visual quality of life (VQoL) for visually impaired people. Twenty-nine groups of up to six patients each were recruited for participation in a “peer group emotional support service” facilitated by trained counselors for a period of six months. Their responses to [Read More]

Improving Autophagy Function Reduces Drusen

by Dan Roberts Researchers at the University of Eastern Finland have discovered that a cleaning mechanism in the center of the retina may be faulty in people who develop age-related macular degeneration (AMD). A cleaning process called autophagy helps clear cellular waste deposits (drusen) that can build up in the retinal tissue. If autophagy diminishes, [Read More]